After #TROPiCS02, we now have NCCN recommendation for the use of 2 distinct ADCs for each MBC subset:
- HER2+ ➡️ T-DM1 & T-DXd
- TNBC ➡️ SG & T-DXd (if HER2-low)
- HR+ ➡️ SG & T-DXd (if HER2-low)
Many more to come: the ADC revolution has just started.
For the DefineMBC team, pink isn’t just a focus in October. We see pink year-round with our proprietary immunofluorescence technology that detects circulating tumor cells. Discover our innovative liquid biopsy for patients with metastatic breast cancer with DefineMBC.